Report of Foreign Issuer (6-k)
April 28 2016 - 9:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 28, 2016
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Semaglutide significantly reduces the risk of major adverse
cardiovascular events in the SUSTAIN 6 trial
Bagsværd, Denmark, 28 April 2016 -
Novo Nordisk today announced
the top-line results from the sixth and last global phase 3a trial, SUSTAIN 6, for semaglutide; a new GLP-1 analogue, which is
administered subcutaneously once weekly in the SUSTAIN trials. This double-blinded trial investigated the long-term cardiovascular
and other safety outcomes of 0.5 mg and 1.0 mg semaglutide compared with placebo, both in addition to standard-of-care. In the
trial, approximately 3,300 people with type 2 diabetes were treated for 104 weeks.
The trial achieved its primary endpoint of showing non-inferiority of
major cardiovascular events (MACE) with semaglutide compared with placebo, as well as a statistically significant reduction in
cardiovascular risk. In the trial, around 250 MACE were accrued. The primary endpoint of the study was defined as the composite
outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.
The safety profile of semaglutide in SUSTAIN 6 was as expected and consistent
with previous semaglutide clinical studies.
“We are very encouraged by the potential for reduction of CV risk
in people with type 2 diabetes with semaglutide based on the results of SUSTAIN 6. In addition to the strong efficacy profile,
we have also established the safety profile for semaglutide by concluding the six SUSTAIN trials” says Mads Krogsgaard Thomsen,
executive vice president and chief science officer of Novo Nordisk. “With the strong results from SUSTAIN 6, we look forward
to the regulatory filing of semaglutide.”
Novo Nordisk expects to file semaglutide for regulatory review in the
US and EU in the fourth quarter of 2016.
About semaglutide
Semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue that can
help people with type 2 diabetes achieve substantial improvement of blood glucose with a low risk of hypoglycaemia. In addition,
semaglutide induces weight loss by decreasing appetite and food intake. Semaglutide administered subcutaneously once weekly is
in phase 3
Page 2 of 3
development for the treatment of type 2 diabetes. Furthermore, semaglutide
is currently being developed in an oral tablet version for treatment of type 2 diabetes as well as in once-daily subcutaneous versions
for treatment of type 2 diabetes and weight management.
About the SUSTAIN clinical programme
The SUSTAIN programme is a phase 3 clinical programme comprising six
global trials of semaglutide administered subcutaneously once weekly encompassing more than 7,000 people with type 2 diabetes.
SUSTAIN 1 – a 30-week efficacy and safety
trial of semaglutide versus placebo in 388 drug-naïve people with type 2 diabetes. The results were reported in July 2015.
SUSTAIN 2 – a 56-week efficacy and safety trial of semaglutide
versus sitagliptin once- daily as add-on to metformin and/or TZD in 1,231 people with type 2 diabetes. The results were reported
in December 2015.
SUSTAIN 3 – a 56-week efficacy and safety trial
of semaglutide versus 2.0 mg exenatide once-weekly as add-on to 1–2 oral antidiabetic drugs in 813 people with type 2 diabetes.
The results were reported in September 2015.
SUSTAIN 4 – a 30-week efficacy and safety trial of semaglutide
versus insulin glargine once-daily as add-on to metformin with or without sulfonylurea in 1,089 insulin-naïve people with
type 2 diabetes. The results were reported in November 2015.
SUSTAIN 5 – a 30-week efficacy and safety trial of semaglutide
versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in 397 people with type 2 diabetes.
The results were reported in February 2016.
SUSTAIN 6 – a 2-year trial to evaluate cardiovascular
and other long-term outcomes with semaglutide in approximately 3,300 people with type 2 diabetes.
Novo Nordisk is a global
healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience
and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and
obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in
more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit
novonordisk.com
, Facebook, Twitter, LinkedIn, YouTube
Page 3 of
3
Further information
Media:
|
Katrine Sperling
|
+45 3079 6718
|
krsp@novonordisk.com
|
Ken
Inchausti (US)
|
+1 609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Daniel Bohsen
|
+45 3079 6376
|
dabo@novonordisk.com
|
Melanie Raouzeos
|
+45 3075 3479
|
mrz@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 31 / 2016
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: April 28, 2016
|
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024